China Resources Double-Crane Pharmaceutical Co Ltd
SSE:600062
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
China Resources Double-Crane Pharmaceutical Co Ltd
Cash from Operating Activities
China Resources Double-Crane Pharmaceutical Co Ltd
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
China Resources Double-Crane Pharmaceutical Co Ltd
SSE:600062
|
Cash from Operating Activities
¥1.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
2%
|
CAGR 10-Years
8%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Cash from Operating Activities
¥4.8B
|
CAGR 3-Years
20%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Cash from Operating Activities
¥11.2B
|
CAGR 3-Years
107%
|
CAGR 5-Years
27%
|
CAGR 10-Years
17%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Cash from Operating Activities
¥4.6B
|
CAGR 3-Years
13%
|
CAGR 5-Years
4%
|
CAGR 10-Years
8%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Cash from Operating Activities
¥8.8B
|
CAGR 3-Years
26%
|
CAGR 5-Years
23%
|
CAGR 10-Years
25%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Cash from Operating Activities
¥4.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
171%
|
CAGR 10-Years
N/A
|
|
China Resources Double-Crane Pharmaceutical Co Ltd
Glance View
In the dynamic landscape of China's pharmaceutical industry, China Resources Double-Crane Pharmaceutical Co Ltd emerges as a key player. It traces its roots back to the early 20th century, embodying a rich history of transformation and innovation. The company seamlessly integrates research, development, production, and sales, making it a formidable force in the healthcare sector. Primarily, it focuses on the production of chemical and biological drugs, catering to a wide range of therapeutic areas such as cardiovascular diseases, anti-infection solutions, and nutritional drugs. Through its comprehensive network, the company not only retains a robust domestic presence but also pushes its products into international markets, driving its revenue growth. Double-Crane's business model thrives on a blend of strategic partnerships and a strong emphasis on R&D. By collaborating with top research institutes and leveraging cutting-edge technology, it innovates new products to meet the rising demands of modern healthcare. The company’s substantial investment in R&D has allowed it to build a strong pipeline of proprietary drugs, ensuring a steady stream of products to boost its market position. With a keen eye on market trends and patient needs, China Resources Double-Crane continually optimizes its production processes and expands its distribution channels. This methodical approach enables the company to enhance its profitability while propelling it as a leader in the pharmaceutical industry.
See Also
What is China Resources Double-Crane Pharmaceutical Co Ltd's Cash from Operating Activities?
Cash from Operating Activities
1.5B
CNY
Based on the financial report for Dec 31, 2025, China Resources Double-Crane Pharmaceutical Co Ltd's Cash from Operating Activities amounts to 1.5B CNY.
What is China Resources Double-Crane Pharmaceutical Co Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
8%
Over the last year, the Cash from Operating Activities growth was -18%. The average annual Cash from Operating Activities growth rates for China Resources Double-Crane Pharmaceutical Co Ltd have been 2% over the past three years , 2% over the past five years , and 8% over the past ten years .